Kong Panpan, Yang Huan, Liu Huifang, Tong Qing, Yi Mamumaimaitijiang-Abula, Zhao Yong, Yan Dong
The First Ward of Hepatobiliary and Pancreatic Surgery, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Eur J Med Res. 2024 Dec 19;29(1):595. doi: 10.1186/s40001-024-02189-5.
CMTM6 has been closely associated with the onset and progression of various tumor types. However, the precise mechanism by which CMTM6 operates in hepatocellular carcinoma remains elusive, necessitating further investigation.
Expression levels of CMTM6 in hepatocellular carcinoma tissues and cells were analyzed using immunohistochemistry and quantitative real-time PCR. The correlation between CMTM6 expression in hepatocellular carcinoma tissues and clinical pathological characteristics, as well as patient prognosis, was investigated. Proliferation and apoptosis of hepatocellular carcinoma cells with silenced or overexpressed CMTM6 were assessed, alongside measurements of β-catenin and Wnt1 protein expression levels. In vivo research was conducted utilizing a murine subcutaneous transplantation model. Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed to elucidate the regulatory mechanism of CMTM6. Additionally, CD66b expression levels in tumor tissue were examined using immunohistochemistry, and the immune infiltration of CMTM6 and tumor-associated neutrophils (TANs) was analyzed.
Elevated expression levels of CMTM6 in hepatocellular carcinoma tissues and cells were found to be associated with poor patient prognosis. Overexpression of CMTM6 in hepatocellular carcinoma cells was demonstrated to promote cellular proliferation and inhibit apoptosis. Mechanistically, CMTM6 expression levels in hepatocellular carcinoma tissues were observed to positively correlate with β-catenin expression. GSEA and KEGG analysis revealed significant enrichment of CMTM6 in the Wnt/β-catenin pathway, indicating its involvement in pathway regulation. Furthermore, CMTM6 was found to be associated with immune infiltration of TANs in hepatocellular carcinoma tissues.
CMTM6 plays a pivotal role in the development and progression of hepatocellular carcinoma through regulation of the Wnt/β-catenin pathway via β-catenin. Moreover, CMTM6 demonstrates the capacity to promote immune infiltration of TANs in hepatocellular carcinoma tissues. Consequently, CMTM6 exhibits potential as both an early diagnostic marker and a novel therapeutic target for patients with hepatocellular carcinoma.
CMTM6与多种肿瘤类型的发生和发展密切相关。然而,CMTM6在肝细胞癌中发挥作用的精确机制仍不清楚,需要进一步研究。
采用免疫组织化学和定量实时PCR分析CMTM6在肝细胞癌组织和细胞中的表达水平。研究肝细胞癌组织中CMTM6表达与临床病理特征以及患者预后之间的相关性。评估CMTM6沉默或过表达的肝细胞癌细胞的增殖和凋亡情况,并检测β-连环蛋白和Wnt1蛋白表达水平。利用小鼠皮下移植模型进行体内研究。进行基因集富集分析(GSEA)和京都基因与基因组百科全书(KEGG)富集分析以阐明CMTM6的调控机制。此外,采用免疫组织化学检测肿瘤组织中CD66b表达水平,并分析CMTM6与肿瘤相关中性粒细胞(TANs)的免疫浸润情况。
发现肝细胞癌组织和细胞中CMTM6表达水平升高与患者预后不良相关。证明CMTM6在肝细胞癌细胞中的过表达促进细胞增殖并抑制凋亡。机制上,观察到肝细胞癌组织中CMTM6表达水平与β-连环蛋白表达呈正相关。GSEA和KEGG分析显示CMTM6在Wnt/β-连环蛋白通路中显著富集,表明其参与通路调控。此外,发现CMTM6与肝细胞癌组织中TANs的免疫浸润相关。
CMTM6通过β-连环蛋白调节Wnt/β-连环蛋白通路在肝细胞癌的发生和发展中起关键作用。此外,CMTM6显示出促进肝细胞癌组织中TANs免疫浸润的能力。因此,CMTM6作为肝细胞癌患者的早期诊断标志物和新型治疗靶点具有潜力。